

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application. Applicant reserved the right for all the cancelled claims.

**LISTING OF CLAIMS:**

Claims 1-41 (cancelled)

Claim 42 (new) A peptide or polypeptide obtained from the armadillo domain of human  $\beta$ -catenin polypeptide which affects the interaction of human  $\beta$ -catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said peptide or polypeptide is selected from a group consisting of peptides or polypeptides having the sequences shown in SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

Claim 43 (new) A peptide or polypeptide obtained from the armadillo domain of human  $\beta$ -catenin polypeptide which affects the interaction of human  $\beta$ -catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said peptide or polypeptide is selected from a group consisting of peptides or polypeptides having the sequences shown in SEQ ID NO: 6 having a mutation in Phe in position 253 or a mutation in His in position 260 or both; SEQ ID NO: 7 having a mutation in Arg in position 274 or a mutation in Lys in position 292 or both; SEQ ID NO: 8 having a mutation in Trp in position 338 or a mutation in Arg in position 342 or a mutation in Lys in position 345 or any combination of mutations thereof ; SEQ ID NO: 9 having a mutation in Lys in position 354 or a mutation in Trp in position 383 or a mutation in Arg

in position 386 or any combination of mutations thereof; SEQ ID NO: 10 having a mutation in Lys in position 394; and SEQ ID NO: 11 having a mutation in Lys in position 435 or a mutation in Arg in position 457 or a mutation in Arg in position 469 or a mutation in His in position 470 or any combination of mutations thereof, wherein said mutation replaces the indicated amino acid with a different amino acid.

**Claim 44** (new) A mutant of the armadillo domain of human  $\beta$ -catenin polypeptide obtained from the armadillo domain of human  $\beta$ -catenin polypeptide which affects the interaction of human  $\beta$ -catenin polypeptide and a transcription factor or tumor suppressor protein, wherein said mutant is selected from a group consisting of mutants of the armadillo domain of human  $\beta$ -catenin polypeptide having a mutation in His in position 470, a mutation in Trp in position 383, a mutation in Arg in position 386, or said mutant is selected from a group consisting of mutants of the armadillo domain of human  $\beta$ -catenin polypeptide having a mutation in Arg in position 386, a mutation in Phe in position 253, a mutation in Arg in position 274, a mutation in Trp in position 338, or said mutant is selected from a group consisting of mutants of the armadillo domain of human  $\beta$ -catenin polypeptide having any combination of mutations in Arg in position 386, Phe in position 253, Arg in position 274 and Trp in position 338, wherein said mutation replaces the indicated amino acid with a different amino acid.

**Claim 45** (new) The mutant according to claim 43 or 44, wherein said mutation replaces the indicated amino acid with an aliphatic amino acid such as alanine, valine, leucine or isoleucine.

Claim 46 (new) The mutant according to claim 45, wherein said mutation replaces the indicated amino acid with alanine.

Claim 47 (new) The peptide or polypeptide of claim 42, 43 or 44, wherein the effect is to inhibit the interaction of  $\beta$ -catenin and said transcription factor or tumor suppressor protein.

Claim 48 (new) The peptide of claim 47, wherein the effect is to inhibit the interaction of  $\beta$ -catenin and a transcription factor or tumor suppressor protein selected from the group of LEF-1, TCF-1, APC 15, conductin, E-cadherin and 20 amino acid repeats of APC.